Enliven Therapeutics Inc (NASDAQ:ELVN)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 1.15. At the close of trading, the stock’s price was $16.51, to imply an increase of 10.73% or $1.6 in intraday trading. The ELVN share’s 52-week high remains $30.03, putting it -81.89% down since that peak but still an impressive 19.44% since price per share fell to its 52-week low of $13.30. The company has a valuation of $809.07M, with an average of 0.49 million shares in intraday trading volume over the past 10 days and average of 273.62K shares over the past 3 months.
Enliven Therapeutics Inc (NASDAQ:ELVN) trade information
After registering a 10.73% upside in the last session, Enliven Therapeutics Inc (ELVN) has traded red over the past five days. The 5-day price performance for the stock is -11.66%, and -18.63% over 30 days. With these gigs, the year-to-date price performance is -26.62%. Short interest in Enliven Therapeutics Inc (NASDAQ:ELVN) saw shorts transact 7.34 million shares and set a 35.28 days time to cover.
The extremes give us $39 and $40 for target low and target high price respectively. As such, ELVN has been trading -142.28% off suggested target high and -136.22% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 19.02% for the past 5-year period. While 2025 is set for a -16.22% return in earnings, projections for the next 5 years are at -18.00% annually.
ELVN Dividends
Enliven Therapeutics Inc has its next earnings report out on 2025-Mar-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Enliven Therapeutics Inc (NASDAQ:ELVN)’s Major holders
Enliven Therapeutics Inc insiders hold 6.42% of total outstanding shares, with institutional holders owning 102.64% of the shares at 109.69% float percentage. In total, 102.64% institutions holds shares in the company, led by ORBIMED ADVISORS LLC. As of 2024-06-30, the company held over 7.96 million shares (or 16.5565% of shares), all amounting to roughly $186.01 million.
The next major institution holding the largest number of shares is FMR LLC with 5.69 million shares, or about 11.8452% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $133.08 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Enliven Therapeutics Inc (ELVN) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 1.12 shares. This is just over 2.29% of the total shares, with a market valuation of $18.5 million. Data from the same date shows that the other fund manager holds a little less at 912.09, or 1.86% of the shares, all valued at about 15.06 million.
